Sky Century Investment (SKYI) Liabilities and Shareholders Equity (2013 - 2026)
Sky Century Investment's (SKYI) quarterly Liabilities and Shareholders Equity came in at $128573.0 in Q2 2026, up 3.32% year-on-year from $124437.0 in Q2 2025, and up 18.41% on a QoQ basis from $108586.0 in Q1 2026.
Sky Century Investment (SKYI) Liabilities and Shareholders Equity (2013 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $128573.0 in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 3.32% year-over-year to $128573.0 in Q2 2026; TTM through May 2026 was $462424.0, a 63.01% increase from a year earlier, with the FY2025 full-year figure at $111742.0, up 17.15% from the prior year.
- Liabilities and Shareholders Equity for Q2 2026 stood at $128573.0, up from $108586.0 in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for SKYI reached as high as $128573.0 in Q2 2026 and fell as low as $63858.0 in Q1 2025.
- Historically, Liabilities and Shareholders Equity has averaged $106586.1 across 3 years, with a median of $111742.0 in 2025.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 70.04% in 2026 and fell as far as 3.32% in 2026.
- Year by year, Liabilities and Shareholders Equity stood at $95384.0 in 2024, then rose by 19.02% to $113523.0 in 2025, then climbed by 13.26% to $128573.0 in 2026.
- Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $128573.0 in Q2 2026, $108586.0 in Q1 2026, and $113523.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 6.71 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 69.30 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | 128,573.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 128,573.00 |
| Feb 28, 2026 | 108,586.00 |
| Nov 30, 2025 | 113,523.00 |
| Aug 31, 2025 | 111,742.00 |
| May 31, 2025 | 124,437.00 |
| Feb 28, 2025 | 63,858.00 |
| Aug 31, 2024 | 95,384.00 |
| Aug 31, 2014 | 515.00 |
| May 31, 2014 | 515.00 |
| Feb 28, 2014 | 515.00 |
| Nov 30, 2013 | 5,565.00 |
| Aug 31, 2013 | 479.00 |
| May 31, 2013 | 154.00 |